Level Bio AB (publ)

NGM:LEVBIO Voorraadrapport

Marktkapitalisatie: SEK 20.2m

Level Bio Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Joakim Granemo

Algemeen directeur

SEK 1.0m

Totale compensatie

Percentage CEO-salaris95.7%
Dienstverband CEO1.3yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur4.8yrs

Recente managementupdates

Recent updates

Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

Jun 02
Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?

Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

Feb 10
Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?

I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

Nov 03
I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease

AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Aug 18
AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

Mar 07
Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?

Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Nov 22
Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?

Analyse CEO-vergoeding

Hoe is Joakim Granemo's beloning veranderd ten opzichte van Level Bio's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-SEK 12m

Mar 31 2024n/an/a

-SEK 11m

Dec 31 2023SEK 1mSEK 981k

-SEK 9m

Sep 30 2023n/an/a

-SEK 5m

Jun 30 2023n/an/a

-SEK 4m

Mar 31 2023n/an/a

-SEK 4m

Dec 31 2022SEK 866kSEK 768k

-SEK 2m

Compensatie versus markt: De totale vergoeding ($USD 94.73K ) Joakim } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 241.30K ).

Compensatie versus inkomsten: De vergoeding van Joakim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Joakim Granemo (38 yo)

1.3yrs

Tenure

SEK 1,025,000

Compensatie

Mr. Joakim Granemo is Chief Executive Officer of Level Bio AB (publ) from August 2023 and its Director from October 2022.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Joakim Granemo
CEO & Director2.1yrsSEK 1.03mgeen gegevens
Ulrica Karlsson
CFO & Directorno dataSEK 928.00kgeen gegevens
Helene Olsson
Director of Cybergene ABno dataSEK 605.00kgeen gegevens
Mikael Havsjo
Director13.7yrsSEK 549.00kgeen gegevens
Artur Aira
Chairman6.8yrsSEK 50.00kgeen gegevens
Tobias Schön
Director1.8yrsSEK 50.00k5.1%
SEK 1.0m
Neven Zoric
Director4.8yrsSEK 50.00kgeen gegevens
Claes Gustafsson
Director of Techtum Lab ABno dataSEK 934.00kgeen gegevens

4.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LEVBIO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).